The characteristic lesion in acute myeloid leukemia (AML) is the failure of myeloid cells to differentiate normally, leading to the accumulation of immature blast cells (BC) in the bone marrow. We determined whether BC and leukemia colony-forming cells (L-CFC) from AML patients could differentiate in vitro after short-term culture with interferon-gamma (IFNy), 1.25 dihydroxyvitamin D, (D3). retinoic acid (RA), tumor necrosis factor-alpha (TNFa), and granulocyte-monocyte colony-stimulating factor (GM-CSF). Expression of myeloid differentiation antigens CD15, CD14, CD33, and p124 was determined on the BC by immunofluorescence and on the L-CFC by monoclonal antibody (MoAb) and complement (C)-mediated cytotoxicity followed by cloning in methylcellulose. We found that 26 of 39 (67%) cases demonstrated changes in the expression of myeloid differentiation antigens on the BC, and 6 of 7 (86%) cases showed an altered L-CFC myeloid antigen phenotype after short-term culture with differentiating agents. Alterations in myeloid antigen expression in the L-CFC population correlated with a reduction in L-CFC cloning potential. In the BC, alterations of myeloid differentiation antigens occurred in a manner consistent with those observed during normal myelopoiesis. For example,
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CUTE MYELOID leukemia (AML) is a malignant
A proliferation of immature myeloid cells that generally fail to differentiate to end-stage mature cells. Cells from patients with AML are classified in the French-AmericanBritish (FAB) system according to histochemical and morphologic markers.' The development of murine monoclonal antibodies (MoAbs) to myeloid differentiation antigens has added immunophenotyping to morphology and histochemistry for assessing the phenotype diversity in AML. AML blast cells (BC) express antigens characteristic of discrete myeloid subpopulations, strengthening the belief that the malignant transformation can occur at multiple points during
The cell-surface expression of differentiation antigens changes during normal myelopoiesis such that the array of surface markers expressed by immature progenitor cells differs from that of mature monocytes and neutrophils. Additionally, different myeloid cell types express lineagespecific surface markers that allow their identification using MoAbs. Immature progenitor cells express the pl24 and CD33 antigen^.^.^ Although the p124 antigen is found on early progenitor cells from all myeloid subclasses, it is absent from the more primitive pluripotent progenitor cell population obtained from long-term bone marrow cultures established from normal donors.' During the differentiation of granulocyte-monocyte-colony forming units (CFU-GM) to CFU-G, a proportion of these cells express CD15,6 in addition to retaining p124 and CD33 expression. The CD14 antigen has been detected on late progenitor cells of the CFU-GM but not on early CFU-GM or erythroid (BFU-E) progenitors. 6 Further differentiation of CFU-GM to mature monocytes results in the induction of CD14 antigens,' continued expression of CD333 and persistence of p124 on only a small percentage of the c e k 4 Differentiation along CD14 antigen expression (a late-stage monocyte antigen) increased on BC from 12 of 39 (31 %) cases, and p124 (an antigen expressed both by myeloid progenitor cells and by a subset of monocytes) increased on 15 of 39 (38%) cases.
Changes in the expression of CD33 antigens (expressed normally by myeloid progenitor cells and by mature monocytes) on the BC were variable, with 7 of 29 cases (24%) showing a decrease and 7 of 29 cases (24%) showing an increase. When comparisons were made between pairs of differentiation agents that caused the altered expression of an antigen on either the BC or L-CFC of a patient, the majority of changes were in the same direction (either both "increased" or both "decreased"). This suggests that the direction of antigen change is characteristic of the leukemia cell subpopulation for each patient and not of the stimulatory agent. This study demonstrates that cells from more than two thirds of AML cases examined responded to various differentiation agents in vitro as measured by changes in the expression of myeloid cell-associated surface antigens and by alterations in cloning potential of the L-CFC, a finding of potential clinical significance. 0 1990 by The American Society of Hematology.
the neutrophil pathway is characterized by the expression of high levels of CD15' and low amounts of CD14.
The majority of cases of AML are positive for at least one of the following antigens: CD15, CD14, CD33, or p124.'We chose to study the expression of these four myeloid-cellassociated antigens because of their high frequency of expression on myeloid leukemia cells, and for their differential expression on myeloid cells during myelopoiesis. CDl5 antigens are found on greater than 88% of all cases of AML (unpublished observations, March 1989). Expression of the CD14 antigen is generally restricted to FAB subclasses M4 and M5 in keeping with CD14 expression on normal monocytes, and is found on approximately 33% of all cases of AML.' Expression of p124 and CD33 is found on approximately 48% and 67% of all cases of AML, respectively (unpublished observations, March 1989). Phenotypic studies examining the surface phenotype of the leukemia colonyforming cell (L-CFC) population in AML, the putative leukemia stem have found that L-CFC can be classified according to the pattern of myeloid differentiation antigen expressi~n.~-'~ Further, L-CFC can display a less-differentiated phenotype when compared with the BC population from each patient.
Early studies of the induction of myeloid differentiation in BC from AML patients examined changes in morphology or histochemical markers."-'* More recent report^'^.'^ studied the effects of hematopoietic growth factors on growth and proliferation of AML BC and L-CFC. However, these studies did not examine changes in the expression of myeloid differentiation antigens on the L-CFC, nor did they examine the effects of growth factors on both BC and L-CFC populations from the same patient. In this manuscript, we report our findings of the inducibility to differentiation of the BC and the L-CFC in AML. We compared the response of the BC and the L-CFC from seven patients to various differentiation stimuli. In an additional 32 cases, we examined the effects of short-term culture with differentiating agents in the BC only and compared the responses among these patients.
The aim of this study was to determine whether culture with differentiating agents known to induce differentiation in the human myeloid leukemia cell lines HL-60 and U937 would cause changes in the myeloid phenotype of BC and L-CFC from patients with AML. Various cytokines and vitamins were chosen for study based on their known effects in vitro in inducing differentiation in leukemia cells and cell lines and on their potential clinical use in ~i t r o . '~, '~-'~ Characteristics of a shift to a more differentiated state, including the induction of the expression of mature myeloid antigens and a reduction in proliferation and cloning efficiency, were examined in both the BC and L-CFC populations. Our findings demonstrate that alterations of myeloid differentiation antigens occur in AML in a manner consistent with that observed during normal myelopoiesis, such as an increase in the expression of CD14 antigens and alterations in the expression of CD33 and p124.
MATERIALS AND METHODS
Patients. Blast cells from the peripheral blood (PB) (n = 29) and bone marrow (BM) (n = 11) from 39 patients with AML were evaluated in this study. Samples were obtained after informed consent as part of the immunophenotyping study (no. 8361) conducted by the Cancer and Leukemia Group B (CALGB).2.20 Most samples were obtained from patients at diagnosis (n = 36), and three samples were obtained at first relapse ( MoAbs. Purified murine MoAbs PM-81, AML-2-23, AML-1-99, and W6/32, were produced from ascites fluid in our laboratory. MY9 was used as ascites fluid provided by Dr James D. Griffin, Dana Farber Cancer Center, Boston, MA. PM-81 recognizes the lacto-N-fucopentaose I11 glycolipid moiety (CDl5) on granulocytes and, to a much lesser extent, on normal monocytes? AML-2-23 recognizes the gp55 moiety (CD14) highly expressed on normal monocytes and macrophages. This antigen is induced on HL-60 promyelocytic leukemia and U937 leukemia cells after a 48-to 72-hour culture with a variety of differentiating agents, including gamma interferon (IFNy) and 1,25 dihydroxyvitamin D3. ' AML-I-99 recognizes a 124-Kd protein (p124) immunoprecipitated from surface-iodinated cell lysates from the U937 leukemia cell line and is detected on progenitor cells of the CFU-GM, BFU-E, and CFU-GEMM subcla~ses.~ However, the p124 antigen is absent on a more immature progenitor cell population capable of regenerating all myeloid progenitor subclasses on long-term bone marrow feeder layer culture^.^ MY9 detects a 67-Kd protein (CD33) on progenitor cells and monocyte^.^ W6/32 recognizes the human class I histocompatibility HLA glycoproteins. 22 PB or BM were incubated with 1 pg of purified MoAb or with a saturating amount of ascites (MY9, 1:400 dilution), as previously described! Antibody binding was detected using fluorescein isothiocyanate (F1TC)-conjugated, affinity-purified, goat anti-mouse F(ab'), immunoglobulin G (IgG) and IgM antibodies (Boehringer Mannheim Biochemicals, Indianapolis, IN). Flow cytometry was performed on an Ortho System 50H cytofluorograph interfaced to a 2150 computer, using linear amplification of the green fluorescence scale. Two thousand to 5,000 cells from each antibody-stained sample were analyzed. Negative controls included no primary antibody (autoflue rescence) and incubation with supernatant from P3-X63Ag8 (P3), an IgGl secreting murine myeloma cell line. Blast cells were considered positive for antigen binding if 20% or more of the blast cell region stained with a particular antibody in e x m s of the negative control.
AML patient cells isolated as described above were treated at 4 x lo6 cells/mL with saturating amounts of MoAb (saturation was determined by flow cytometry and cytotoxicity using HL-60 or U937 leukemia cell lines) for 15 minutes, followed by incubation for 60 minutes with rabbit serum as a source of complement (C) (Pel Freeze, Brown Deer, WI) at a final dilution of 1:6, as previously d e~r i b e d . 2~ After washing, each tube of cells was resuspended to the same volume to compare relative loss of L-CFC numbers among treatment groups. Cytotoxicity was determined by enumerating viable cells, and a 300-pL aliquot from each sample was plated in methylcellulose for colony growth. Negative controls included incubation with medium alone, medium plus C , and an irrelevant IgM MoAb, sIgA39, plus C' . Colony numbers from dishes representing anti-myeloid MoAb and C' treatment were compared with the control colony number, and the percentage of L-CFC positive for a particular antigen was determined by:
Percentage L-CFC Positive for Antigen
Indirect immunoJluorescence and flow cytometry.
MoAb and complement-mediated cytotoxicity.
Mean Colony No. in MoAb plus
Mean Colony No. in Control Dishes Total blast cells were phenotyped from the PB or BM from AML patients by flow cytometry, and the L-CFC populations were phenotyped by colony *BC, total blast cell population; L-CFC, leukemia colony-forming cell population. The L-CFC were considered positive for a particular antigen if 20% or more of the colony-forming cells were eliminated by MoAb plus C' treatment. PB and BM were plated at various concentrations ranging from 5 x IO4 to 2 x 10' cells per dish in methylcellulose cultures containing 0.8% methylcellulose; 30% fetal bovine serum (FBS); 1% deionized bovine serum albumin (BSA); 10% GCT (GIBCO, Grand Island, NY) or PHA-LCM; 5 x Leukemia cell colony assay. mol/L P-mercaptoethanol; and 2 mmol/L glutamine. PHA-LCM was prepared from mononuclear cell fractions from normal donors. Cells were plated in duplicate in 35-mm gridded petri dishes (Nunc, Inc, Naperville, IL) and incubated at 37OC for 10 to 14 days in a humidified 5% CO, incubator. Colonies were defined as clusters of more than 40 cells and were enumerated using an inverted microscope. Representative colonies from each patient were picked from methylcellulose by aspiration, disaggregated in medium, centrifuged onto glass slides, and stained with Wright's-Giemsa to verify leukemia origin.
Fresh blast cells were cultured at 2 x lo6 cells/mL in Teflon beakers (to reduce adherence) for 4 The median as well as the average percentage of cells recovered from culture are reported in Table 2 due to the skewness of the distributions of these values. Aliquots of the cells from each group were examined for antigen expression on the BC using indirect immunofluorescence and flow cytometry, and for the effects of these agents on antigen expression and colony formation in the L-CFC population after MoAb plus C-mediated cytotoxicity followed by methylcellulose cloning. No fresh differentiating agents were added to the methylcellulose culture dishes.
RESULTS
Cells from 39 patients with AML were studied for changes in the expression of myeloid differentiation antigens on the L-CFC and BC populations after a 4-day culture with differentiating agents. Of the 39 cases examined, cells from 13 patients (no. 1 through 13) formed leukemia colonies when fresh cells were cultured, and 3 of the 13 (no. 1 through 3) also formed leukemia colonies after a 4-day suspension culture with differentiation-inducing agents. Cells from four additional patients (no. 14 through 17) formed L-CFC after the 4-day culture but did not form L-CFC with freshly plated cells. Thus, we were able to evaluate the effects of differentiating agents on L-CFC growth and antigen expression from seven patients. Cells from the remaining 32 patients did not form colonies in methylcellulose after culture, and only the total blast cell population could be analyzed for alterations in myeloid antigen expression after culture with these compounds.
The BC pheno-
Patients.
Phenotypic analysis of leukemia cells.
type was determined from freshly isolated blast cells using a panel of anti-myeloid MoAbs by indirect immunofluorescence and flow cytometry. We also determined the L-CFC phenotype of 13 patients using fresh cells (before culture), with the same panel of anti-myeloid MoAbs in a cytotoxicity assay followed by colony formation in methylcellulose. As shown in Table 1 , most of the cases expressed CD15 (98% and 85%, respectively) and CD33 (68% and 77%, respectively) on the BC and L-CFC populations, and the majority were positive for p124 antigens on the L-CFC population (83%). All patients (100%) were positive in both the BC and L-CFC populations for HLA class I (data not shown). In comparisons of MoAb binding between the L-CFC and BC in the 13 cases studied, there was a marked discordancy in antigen expression between these two populations in eight of the cases studied. In these cases, the BC or the L-CFC was determined to be antigen-negative for a particular myeloid differentiation antigen (less than 20% antigen-positive cells), while the other leukemia cell subpopulation was positive (greater than 20% positive cells). Of the three instances in which the BC expressed antigens not found on the L-CFC, one case each involved CD15, p124, and CD33. Of the five instances in which the L-CFC expressed antigens not found on the BC, one case involved CD14, two cases involved p124, and three cases involved CD33 (Table 1) . Additionally, there were several cases in which a patient's BC and L-CFC differed by 20% or greater in the percentage of antigenpositive cells. These variations in antigenic phenotype are shown by the underlined values in Table 1 .
Recovery of blast cells after short-term culture with diflerentiating agents. Enumeration of viable cells after 4-day culture in Teflon beakers with various differentiating agents was determined by acridine orange/ethidium bromide vital dye staining. We determined both the recovery of viable cells from the control culture and the percentage of viable cells recovered after culture with each differentiating agent as compared with the viable cell number in the control culture. Cultures of blast cells in medium alone from some cases showed little or no evidence of cell growth as determined by the viable cell recovery. The median percentage recovery of viable cells was 48%, and the range was 8% to 112% (data not shown). When the viable cell recovery from cultures containing various differentiating agents was compared with the cell recovery from the control culture, we observed that there was little, if any, effect on viable cell recovery from any particular differentiating agent. Rather, the median recovery from all samples was greater than 76% for all of the differentiating agents used (Table 2) . Percentage recovery was determined from the ratio of viable cells from cultures containing differentiating agents to the number in the control culture as described in the Materials and Methods section.
Altered myeloid antigen expression in the BC population.
Alterations in myeloid antigen phenotype in the BC population were analyzed by immunofluorescence and flow cytometry in 39 patients after 4-day culture with various differentiating agents. To evaluate the effects on myeloid antigen phenotype resulting from culture with a particular differentiating agent, we compared the perecentage of cells positive for each myeloid antigen among control-cultured cells and cells from the same patient cultured with various differentiation-inducing agents. We considered a change in the percentage of positive cells of a t least 20% between these two values to be biologically significant. A change of this magnitude would not occur by chance since the withinpatient variation of percentage-positive values is 2% assuming 2,000 cells analyzed and a binomial distribution. Of the 39 cases studied, 26 cases (67%) showed a change of a t least 20% in the expression of a t least one myeloid antigen after 4-day culture with these differentiating agents, and there were several cases in which more than one myeloid antigen was changed. Ten of 38 cases (26%) showed changes in CD15, 13 of 38 (34%) showed changes in CD14, 19 of 39 (49%) showed changes in p124, 11 of 29 (38%) showed changes in CD33, and 5 of 36 (14%) showed changes of HLA class I expression (Table 3) . Common changes are shown in Fig 1, together with the expected alterations in surface myeloid antigen phenotype of normal myeloid cells during differentiation from progenitor cells to mature monocytes and neutrophils.
Comparisons were made between each pair of differentiation-inducing agents to determine whether there was any association between the type of change (increase or decrease in the percentage of antigen-positive cells by at least 20%) and the type of agent that elicited the change. For each pair of agents, a 2 x 2 table was constructed comparing the direction of change for patients who had responded to both agents. The total number of changes and the number of similar changes (both "increased" or both "decreased") were summed over all 2 x 2 tables for each antigen. For CD15, 17 pairs of changes in antigen expression were noted; of these, 10 were in a similar direction. For CD14, 19 of 28 pairs of changes were similar; for p124, 17 of 25 changes were similar; and for CD33, 14 of 20 changes were similar.
EfEffect of differentiating agents on L-CFC growth. fects of differentiation agents on the L-CFC population from' seven cases were assessed by measuring changes in clonogenic potential and by determining changes in the expression of myeloid antigens. Cells from each group were washed extensively after culture before plating in methylcellulose and were plated in the absence of the differentiating agent. As shown in Table 4 , IFN-y, either alone or in combination with 1,25 dihydroxyvitamin D, (D3) or retinoic acid (RA), reduced the clonogenic potential to less than 50% of control numbers in all but one patient. Although only two patients' L-CFC were examined after GM-CSF culture, both demonstrated a decrease in proliferation to 1% and 9% of controls (data not shown).
Effects of differentiating agents on L-CFC phenotype. The antigenic phenotype of the L-CFC was examined after (31) 611 (27) 212 (2 1) 113 (19) 012 (28) 112 (23) 110 (22) 010 (22) 210 (22) 211 (21) 212 120)
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411 (29) 210 ( 1  105  107  89  87  53  2  50  64  2  35  23  3  36  52  12  40  30  14  12  14  79  5  ND  15  16  64  ND  2  ND  16  36  44  107  18  9  17  49  0  177  0  1   Median  36  52  04  18  23 Cells from the BM or PB of AML patients were cultured in suspension for 4 days with various differentiating agents as described in Materials and Methods. After culture, the cells were washed, and an equal number of viable cells from each group were plated in methylcellulose in the absence of the differentiating agent. Colonies were scored at 14 days. Data are displayed as percent of control colony number.
Abbreviation: ND, not done.
short-term culture of total blast cells with various differentiating agents. After culture, the cell suspension was washed and treated with MoAb and C' before plating in methylcellulose. The percentage of L-CFC positive for each antigen was determined by the ratio of the colony number from dishes corresponding to anti-myeloid MoAb plus C' treatment to that of MoAb sIgA39 plus C' treatment within each differentiating agent group. This enabled us to correct for variations among colony numbers due to the anti-proliferative effects of the various differentiating agents when determining the percentage of L-CFC positive for a specific myeloid antigen. To evaluate changes in myeloid antigen expression among culture groups, the percentage of L-CFC expressing a particular antigen was compared between the control culture and those containing various differentiating agents, and a difference of a t least 20% was considered a change. As shown in Table 5 , antigenic changes on the L-CFC occurred in 6 of 7 cases. Six patients showed changes in CD15, with the majority of changes (9 of IO) representing a decrease in antigen expression after culture. Five of 7 patients showed a change in CD14 expression, with 7 of 13 changes representing an increase. Five of 7 patients showed a change in p124 expression, with 8 of 12 changes representing a decrease in expression. Only two patients were analyzed for changes in CD33 expression on L-CFC after culture, and 4 of 5 changes were decreases in antigen expression. Similar to the findings in the BC, there was a strong association between the type of antigen change (either increase or decrease in the percentage of antigen-positive L-CFC) when pairs of agents were compared. For alterations in CD15 expression, 7 of 7 comparisons of pairs of agents showed that the antigenic change within patients were in the same direction. For CD14, 9 of 17 paired comparisons were in the same direction, 8 of 14 comparisons for p124 were in the same direction, and 6 of 6 comparisons for CD33 were in the same direction.
DISCUSSION
This study examined the capacity of fresh blast cells from patients with AML to acquire an altered myeloid phenotype after short-term culture with various differentiating agents. Further, the effects of various differentiating agents on the growth of the clonogenic leukemia cell population (L-CFC) were determined in seven cases. The agents chosen that cause differentiation in the myeloid leukemia cell lines HL-60 and U937 are naturally occurring and thus have potential clinical value for use in vitro. Cases of AML were studied for changes in differentiation-antigen phenotype and for reductions in proliferative capacity and colony formation after culture. Two distinct leukemia subpopulations were examined, the BC and the L-CFC, because of the reported differences in their levels of differentiation and differentiative capacity. Our findings demonstrate that antigenic changes occurred on fresh AML blast cells after culture with these molecules, consistent with changes observed during HL-60 and U937 differentiation.
Of the 39 cases studied, 13 patients formed L-CFC with freshly isolated cells. Similar to the findings of Sabbath et aI6 and Kabral et al," there were several cases in which the L-CFC expressed a different phenotype than the total BC population from the same patient. In our study, this was manifested by differences of at least 20% between the L-CFC and the BC in the percentage of CD15, CD14, CD33, and pl24-positive cells. However, the number of cases examined were too few to conclude that the L-CFC express a lessdifferentiated phenotype than the BC. We would expect that a less-differentiated phenotype would consist of low or absent expression of CD14 and CD15, and high expression of p124 and CD33. However, since p124 is expressed on a subpopulation of monocytes and CD33 is expressed on all monocytes, the expression of these antigens together with CD15 or CD14 would suggest a more differentiated phenotype. Furthermore, we have shown that p124 is not expressed on very early pluripotent progenitor cells, demonstrating that absence of this antigen together with CD14, CD15, and CD33 would define a very immature cell phenotype. Thus, the complete myeloid antigen phenotype, together with FAB morphology, needs to be evaluated to definitively assign an "immature" or "mature" classification to individual cases of AML.
Our finding that IFNy and D3 did not markedly inhibit BC recovery was surprising to us in light of the potent effects of these compounds on L-CFC growth and on BC antigenic modulation. We also did not observe a marked stimulation of blast cell proliferation or recovery after 4-day culture with GM-CSF. However, we observed a marked reduction in L-CFC cloning potential after culture with IFNy, either alone or in combination with D3 or RA. In all but one case (patient 3), the combination of IFNy plus D3 was more inhibitory than either compound alone. These findings suggest to us that the L-CFC population is more susceptible to the growth-inhibitory effects of these mediators than the BC population and that inhibition of L-CFC growth occurs before colony formation by inhibiting the proliferation of L-CFC. Alterations in antigen expression have been described in myeloid leukemia cells after short-term culture with differentiation-inducing compounds.24 In our study, the alteration of myeloid antigen phenotype on the BC population occurred more commonly in the expression of CD14 (13 cases) and p124 (18 cases). Interestingly, the CD14 antigen is commonly expressed in M 4 and M5 leukemias, yet induction of this antigen was seen in three cases of FAB subclass M 2 and one case each of FAB subclass M1 and M3. Of the 15 patient samples in which the percentage of pl24-positive cells increased after culture, five were classified as FAB M 4 or M5. These data are interesting in light of our finding that p124 is expressed on a subset of normal PB monocytes4 and would suggest that the pi24 antigen may be a marker of cells in the monocyte lineage, similar to CD14. This finding also suggests that the increase of p124 antigens on leukemia cells after culture may be the result of differentiation along a monocyte lineage. Thus, we could hypothesize that the pl24 antigen is expressed on progenitor cells of all myeloid subclasses after the pluripotent progenitor cell and is then lost during differentiation OF. the majority of myeloid cells but retained on cells destined to comprise a subset of mature monocytes. Our finding that CD33 expression is also variably altered on leukemia cells after short-term culture with differentiating agents could also be explained in this manner. Those cases in which we observed the loss of CD33 expression by leukemia cells may represent the loss of this progenitor cell marker during differentiation from a very immature myeloid cell, yet the acquisition of CD33 by leukemia cells may occur on those cells that are slightly more mature and are differentiating along the monocyte lineage. Our data support this notion, showing that of the four cases in which CD33 expression was increased after culture, we also observed an increase in pi 24 expression.
Of particular interest is our finding that when comparisons were made between pairs of differentiating agents that caused an altered expression of an antigen on the BC or the L-CFC of a patient, the majority of changes were in the same direction. This finding suggests that the type of antigen change in the percentage of positive cells is an inherent characteristic of the leukemia cell subpopulation from each patient, and not of the stimulatory agent. In support of this, for example, is our finding that a particular differentiation agent may act to cause an increased expression of a myeloid cell-surface antigen in one patient, but may have the opposite effect in another patient. However, the particular direction of antigen change (either an increase or a decrease in the percentage of antigen-positive cells) was highly associated for all compounds that resulted in a change for each patient. These types of analyses may further aid in the determination of the specific differentiation stage represented by each patient's leukemia cell population.
When comparisons were made between cases demonstrating changes in the percentage of myeloid antigen-positive L-CFC and cases demonstrating alterations in cloning potential, we observed that in all but one case there was an association between these two events. However, because of the often profound reductions in the numbers of L-CFC resulting from culture with the various differentiating agents, L-CFC phenotype in many cases was determined on a minority of the total starting population. It is possible that in those cases, changes in the percentage of positive cells reflect the phenotype of the surviving subpopulation of L-CFC rather than alterations in myeloid antigen display of the starting cell population. Although we cannot determine unequivocally with these analyses that changes in antigenic phenotype in the L-CFC population reflect alterations in surface antigen expression on all clonogenic leukemia cells, we believe that differentiative events resulting from these molecules occurred in both the L-CFC and BC. In support of this conclusion are the antigenic changes in the BC, where cell loss due to these differentiating agents was negligible. Additionally, it is possible that normal CFU could have proliferated in culture and that some of the colonies we counted were of normal cell origin. We attempted to avoid this problem by performing cytospin preparations on selected cases and verifying the leukemia cell origin by morphology. Our findings confirmed that the colonies we studied were derived from leukemia cells, and that normal CFU growth did not occur.
In three cases, we determined the antigenic phenotype of the L-CFC on fresh cells and again after 4-day culture. Interestingly, we observed that in 2 of the 3 cases, the L-CFC displayed a different array of cell-surface antigens after 4-day culture with medium alone than they did when the cells were freshly isolated. This marked difference in cellsurface phenotype after culture was not usually seen in the BC population. This difference in surface antigen expression could be due to the selective survival of a subset of L-CFC, to alterations resulting from in vitro culture, or to the shedding of cell-surface antigens. To determine whether alterations in cell-surface antigens were the result of culture with differentiating agents, we compared the percentage of L-CFC positive for each antigen after culture with differentiating agents to the medium-alone (control) culture. Because the only difference between the cultures' conditions was the added growth factor or cytokine, we could determine the specific effect of these agents on antigen expression.
The capacity to change the myeloid phenotype of AML BC and L-CFC has important implications for the treatment of this disease. In autologous bone marrow transplantation for example, bone marrow harvested in remission can be treated with anti-myeloid MoAbs before being reinfused into the patient after ablative therapy. 25 The aim of purging is to eliminate any remaining L-CFC so that regrowth of the leukemic clone cannot occur after transplantation. As shown by our findings, for example, cells from patients displaying antigen-negative or low percentages for various myeloid antigens on their L-CFC can be precultured with various differentiation-inducing agents before purging. The particular differentiating agent chosen, duration of incubation, and concentration would be previously determined by analysis of blast cells and L-CFC in these patients a t disease presentation. This ex vivo treatment may serve not only to change the L-CFC phenotype to augment MoAb lysis, but may also reduce the proliferative ability of the L-CFC population. However, the effects of these differentiating agents on normal progenitor cells must be considered, and choice of compounds, duration of culture, and concentration must be carefully determined. As RA and D3 have been shown to have a negligible effect on normal myeloid progenitor cell growth, and in some cases may stimulate normal colony formation, these differentiating agents offer the best promise for in vitro maturation-inducing the rap^.'^-*^ Such maturation-induction therapy would facilitate an increased efficacy of leukemia cell elimination by MoAb-mediated methods, while sparing normal progenitor cells required for engraftment.
